NCT05251883

Brief Summary

As one of the most common malignant tumors in women, the incidence of ovarian cancer is expected to increase year by year. Due to its lack of typical symptoms and effective screening methods, and the characteristics of implantation and distant metastasis, more than 70% of ovarian cancers were in the metastatic stage at the time of diagnosis. In this study, the investigators will collect large samples of tissue from patients with ovarian cancer, conduct multi-omics studies, and mapped the characteristic maps of the genome and transcriptome of patients with metastatic ovarian cancer, and explore the molecular mechanisms that can be used as new targets for the treatment of ovarian cancer. Besides, the investigators will design and establish a database of metastatic ovarian cancer, integrate multiple omics, imaging, pathology, and clinical information to study their potential relevance, and analyze the relationship between various omics, imaging, pathology, and prognosis, establish ovaries Cancer prediction model.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
6mo left

Started Jan 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress91%
Jan 2022Dec 2026

Study Start

First participant enrolled

January 1, 2022

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

January 9, 2022

Completed
2 months until next milestone

First Posted

Study publicly available on registry

February 23, 2022

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Expected
Last Updated

May 19, 2023

Status Verified

September 1, 2022

Enrollment Period

1.9 years

First QC Date

January 9, 2022

Last Update Submit

May 17, 2023

Conditions

Ovarian Cancer

Keywords

multi-omicsovarian cancer

Outcome Measures

Primary Outcomes (1)

  • Progression-Free-Survival

    The sample will be tested immediately after they are taken from patients and the statistical analysis will be taken through study completion, an average of 3 year

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients with metastatic ovarian cancer from the gynecology clinical department of the Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

You may qualify if:

  • female, ≥18 years old;
  • diagnosed as ovarian cancer by imaging and pathology;
  • did not receive any anti-tumor drug treatment before surgery in the gynecology clinical department of the Sun Yat Sen Memorial Hospital of Sun Yat-Sen University;
  • received ovarian cancer surgery and Follow-up treatment;
  • Patients voluntarily participate in the research of this subject, have good compliance, and can complete the enrollment by the requirements of the trial;
  • Sign informed consent and agree to the collection and use of their data.

You may not qualify if:

  • Patients who have received other anti-tumor treatments or received tumor surgery before enrollment;
  • Patients with malignant tumors in other parts;
  • Patients with uncontrollable neurological, psychiatric, or mental disorders;
  • Poor compliance and inability to Cooperate and describe treatment responders.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Universit

Guangzhou, Guangdong, China

RECRUITING

Related Publications (8)

  • Weidle UH, Birzele F, Kollmorgen G, Rueger R. Mechanisms and Targets Involved in Dissemination of Ovarian Cancer. Cancer Genomics Proteomics. 2016 11-12;13(6):407-423. doi: 10.21873/cgp.20004.

    PMID: 27807064BACKGROUND

  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.

    PMID: 30207593BACKGROUND

  • Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017 May;41:3-14. doi: 10.1016/j.bpobgyn.2016.08.006. Epub 2016 Oct 3.

    PMID: 27743768BACKGROUND

  • Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013 Apr;49(6):1374-403. doi: 10.1016/j.ejca.2012.12.027. Epub 2013 Feb 26.

    PMID: 23485231BACKGROUND

  • Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019 Jul;69(4):280-304. doi: 10.3322/caac.21559. Epub 2019 May 17.

    PMID: 31099893BACKGROUND

  • Deng K, Yang C, Tan Q, Song W, Lu M, Zhao W, Lou G, Li Z, Li K, Hou Y. Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients. Gynecol Oncol. 2018 Sep;150(3):460-465. doi: 10.1016/j.ygyno.2018.06.022. Epub 2018 Jul 9.

    PMID: 30001833BACKGROUND

  • Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017 Feb;14(1):9-32. doi: 10.20892/j.issn.2095-3941.2016.0084.

    PMID: 28443200BACKGROUND

  • Piver MS. Treatment of ovarian cancer at the crossroads: 50 years after single-agent melphalan chemotherapy. Oncology (Williston Park). 2006 Sep;20(10):1156, 1158. No abstract available.

    PMID: 17024868BACKGROUND

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

we will collect samples of tissue from patients with ovarian cancer, conduct multi-omics studies, and mapped the characteristic maps of the genome and transcriptome of patients with metastatic ovarian cancer.

MeSH Terms

Conditions

Ovarian Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleUrogenital NeoplasmsGenital DiseasesEndocrine System DiseasesGonadal Disorders

Study Officials

  • Huaiwu Lu

    The Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    STUDY DIRECTOR

Central Study Contacts

Huaiwu Lu, Study Director

CONTACT

+86 18688395806luhuaiwu@mail.sysu.edu.cn

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
3 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 9, 2022

First Posted

February 23, 2022

Study Start

January 1, 2022

Primary Completion

December 1, 2023

Study Completion (Estimated)

December 1, 2026

Last Updated

May 19, 2023

Record last verified: 2022-09

Locations

CN(1)